Caitong International Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Caitong International Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19	Buy	+5	New	+$35	﹤0.01%	2081

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caitong International Asset Management's LFCR Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Lifecore Biomedical (LFCR) in Q1 2026: 5 shares worth $19. The stake represents ﹤0.01% of the portfolio and ranks #2081 among its holdings.

105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

Caitong International Asset Management held 5 shares of Lifecore Biomedical worth $19 as of Q1 2026.
Lifecore Biomedical was a new Caitong International Asset Management position in Q1 2026.
Lifecore Biomedical made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2081 holding.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.